EagleClaw Capital Management’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.72M | Sell |
23,712
-3,124
| -12% | -$468K | 0.5% | 58 |
|
|
2026
Q1 | $4.1M | Sell |
26,836
-846
| -3% | -$130K | 0.57% | 50 |
|
|
2025
Q4 | $3.82M | Sell |
27,682
-400
| -1% | -$52.4K | 0.55% | 50 |
|
|
2025
Q3 | $3.6M | Buy |
28,082
+3,174
| +13% | +$387K | 0.5% | 52 |
|
|
2025
Q2 | $3.01M | Hold |
24,908
| – | – | 0.45% | 59 |
|
|
2025
Q1 | $2.78M | Sell |
24,908
-226
| -0.9% | -$24.1K | 0.44% | 65 |
|
|
2024
Q4 | $2.45M | Buy |
25,134
+2,700
| +12% | +$288K | 0.39% | 67 |
|
|
2024
Q3 | $2.58M | Sell |
22,434
-1,850
| -8% | -$210K | 0.43% | 67 |
|
|
2024
Q2 | $2.59M | Hold |
24,284
| – | – | 0.47% | 62 |
|
|
2024
Q1 | $2.35M | Buy |
24,284
+660
| +3% | +$67.7K | 0.43% | 69 |
|
|
2023
Q4 | $2.39M | Buy |
23,624
+300
| +1% | +$29K | 0.5% | 63 |
|
|
2023
Q3 | $2.38M | Buy |
23,324
+750
| +3% | +$76.1K | 0.54% | 62 |
|
|
2023
Q2 | $2.28M | Sell |
22,574
-750
| -3% | -$75K | 0.52% | 60 |
|
|
2023
Q1 | $2.15M | Sell |
23,324
-994
| -4% | -$86.8K | 0.51% | 64 |
|
|
2022
Q4 | $2.21M | Sell |
24,318
-200
| -0.8% | -$16.8K | 0.53% | 63 |
|
|
2022
Q3 | $1.86M | Sell |
24,518
-375
| -2% | -$31.1K | 0.52% | 64 |
|
|
2022
Q2 | $2.1M | Buy |
24,893
+83
| +0.3% | +$7.28K | 0.57% | 59 |
|
|
2022
Q1 | $2.18M | Sell |
24,810
-150
| -0.6% | -$13K | 0.5% | 62 |
|
|
2021
Q4 | $2.18M | Buy |
24,960
+400
| +2% | +$33.2K | 0.48% | 60 |
|
|
2021
Q3 | $2M | Buy |
24,560
+650
| +3% | +$58.5K | 0.52% | 62 |
|
|
2021
Q2 | $2.18M | Buy |
23,910
+1,925
| +9% | +$171K | 0.56% | 56 |
|
|
2021
Q1 | $1.88M | Hold |
21,985
| – | – | 0.54% | 58 |
|
|
2020
Q4 | $2.08M | Hold |
21,985
| – | – | 0.66% | 49 |
|
|
2020
Q3 | $1.91M | Buy |
21,985
+875
| +4% | +$75.8K | 0.67% | 48 |
|
|
2020
Q2 | $1.84M | Sell |
21,110
-950
| -4% | -$82K | 0.72% | 49 |
|
|
2020
Q1 | $1.81M | Sell |
22,060
-55
| -0.2% | -$4.91K | 0.86% | 43 |
|
|
2019
Q4 | $2.09M | Hold |
22,115
| – | – | 0.77% | 44 |
|
|
2019
Q3 | $1.92M | Buy |
22,115
+400
| +2% | +$35.9K | 0.78% | 41 |
|
|
2019
Q2 | $1.98M | Sell |
21,715
-2,519
| -10% | -$213K | 0.86% | 36 |
|
|
2019
Q1 | $2.09M | Buy |
24,234
+558
| +2% | +$44.8K | 0.95% | 32 |
|
|
2018
Q4 | $1.82M | Hold |
23,676
| – | – | 0.95% | 32 |
|
|
2018
Q3 | $1.83M | Buy |
23,676
+446
| +2% | +$33K | 0.8% | 42 |
|
|
2018
Q2 | $1.57M | Buy |
23,230
+245
| +1% | +$16.9K | 0.76% | 46 |
|
|
2018
Q1 | $1.66M | Buy |
22,985
+781
| +4% | +$59.5K | 0.84% | 44 |
|
|
2017
Q4 | $1.67M | Buy |
22,204
+2,511
| +13% | +$189K | 0.84% | 47 |
|
|
2017
Q3 | $1.52M | Sell |
19,693
-670
| -3% | -$50.6K | 0.86% | 49 |
|
|
2017
Q2 | $1.52M | Hold |
20,363
| – | – | 0.89% | 45 |
|
|
2017
Q1 | $1.36M | Sell |
20,363
-223
| -1% | -$14.9K | 0.82% | 49 |
|
|
2016
Q4 | $1.34M | Hold |
20,586
| – | – | 0.85% | 47 |
|
|
2016
Q3 | $1.45M | Buy |
20,586
+140
| +0.7% | +$10.2K | 0.93% | 43 |
|
|
2016
Q2 | $1.51M | Hold |
20,446
| – | – | 1.01% | 36 |
|
|
2016
Q1 | $1.32M | Sell |
20,446
-232
| -1% | -$15.8K | 0.9% | 42 |
|
|
2015
Q4 | $1.6M | Sell |
20,678
-224
| -1% | -$17.8K | 1.06% | 35 |
|
|
2015
Q3 | $1.72M | Sell |
20,902
-412
| -2% | -$36.7K | 1.21% | 32 |
|
|
2015
Q2 | $1.88M | Sell |
21,314
-168
| -0.8% | -$15.4K | 1.2% | 33 |
|
|
2015
Q1 | $1.9M | Sell |
21,482
-111
| -0.5% | -$9.85K | 1.23% | 32 |
|
|
2014
Q4 | $1.79M | Sell |
21,593
-112
| -0.5% | -$9.28K | 1.18% | 34 |
|
|
2014
Q3 | $1.83M | Buy |
21,705
+139
| +0.6% | +$11.2K | 1.24% | 35 |
|
|
2014
Q2 | $1.75M | Buy |
21,566
+531
| +3% | +$41.8K | 1.18% | 34 |
|
|
2014
Q1 | $1.61M | Buy |
+21,035
| New | +$1.53M | 1.16% | 35 |
|
Other funds holding NVS
EagleClaw Capital Management's NVS Position: Q2 2026 in Review
EagleClaw Capital Management reduced its Novartis (NVS) stake by 12% in Q2 2026, selling an estimated $468K and leaving 23,712 shares worth $3.72M. The position accounts for 0.5% of the portfolio, ranked #58.
EagleClaw Capital Management first reported a position in NVS in Q1 2014 and has held it in 50 quarters since. The position peaked at $4.1M in Q1 2026. 1,612 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- EagleClaw Capital Management held 23,712 shares of Novartis worth $3.72M as of Q2 2026.
- EagleClaw Capital Management sold 3,124 Novartis shares in Q2 2026, an estimated $468K.
- Novartis made up 0.5% of EagleClaw Capital Management's portfolio in Q2 2026, its #58 holding.
- EagleClaw Capital Management first reported a position in Novartis in Q1 2014 and has held it in 50 quarters since.
- EagleClaw Capital Management's Novartis position peaked at $4.1M in Q1 2026.
- 1,612 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on EagleClaw Capital Management's 13F filing for Q2 2026, filed 10 Aug 2026.